Development And Validation Of Rp-Hplc Method For Simultaneous Estimation Of Dapagliflozin And Saxagliptin In Bulk As Per Ich
Keywords:
Dapagliflozin, Saxagliptin and RP-HPLCAbstract
In the present work, a rapid, specific, accurate and precise reversed phase high performance liquid chromatographic (RP-HPLC) method has been developed and validated for simultaneous determination of Dapagliflozin and Saxagliptin in bulk and pharmaceutical dosage form. Successful chromatographic separation of Dapagliflozin (DGN) and Saxagliptin (SGN) was carried out with altima C18 column (150 ×4.6 mm, 5 μm) with mobile phase consisted of a mixture of Acetonitrile and Potassium dihyrogen phosphate buffer in the ratio of 35:65 v/v and the pH of the buffer was adjusted to 5.5, delivered at a flow rate of 1.0 ml/min. The eluents are monitored by PDA detector and peaks values were measured at 225 nm. The retention times for DGN and SGN were 2.953 min and 2.209 min respectively. The present analytical method was validated according to ICH guidelines (ICH, Q2 R1). The linearity study of DGN and SGN was found in the concentration range of 10-50 μg/ml for both and coefficient of variance was 0.997 and 0.998 respectively. % recovery was found to be 100.19% and 99.81 % for DGN and Saxagliptin respectively. LOD was 1.10 μg/ml and 1.18 μg/ml and LOQ was 3.01 μg/ml and 3.12 μg/ml for DGN and SGN respectively. It inferred that the developed method was successfully applied for the simultaneous estimation of DGN and SGN in bulk and could be used for the routine analysis of the studied drugs in quality control laboratories.
Downloads
Metrics
References
Dhillon S, Saxagliptin: A review in type 2 diabetes, Drugs 2015; 75:1783-1796.
Singhal M, Rasania S, Gaur A, Vishnu VM, Raju SV,Upadhyay Y, Overview on sodium glucose transport inhibitors as a therapeutic tool against diabetes mellitus, Global Journal of Pharmacology 2012; 6:86-93.
Manasa S, Dhanalakshmi K, Nagarjuna Reddy G and Kavitha B: Method development and validation of Dapagliflozin API by UV-Spectroscopy. International journal of pharmaceutical sciences review and research. 2014; 27(1): 270-272.
Jani BR, Shah KV and Kapupara PP: Development and Validation of UV- Spectroscopic first derivative method for simultaneous estimation of Dapagliflozin and Metformin Hydrochloride in synthetic mixture. Journal of bioequivalence studies. 2015; 1(1): 1-8.
Chitra KP, Eswaraiah CM and Rao BMV: Unique UV Spectrophotometric method for reckoning of Dapagliflozin in bulk and Pharmaceutical Dosage forms. Journal of Chemical and Pharmaceutical Research 2015; 7(9): 45-49.
Jeyabaskaran M, Rambabu C and Dhanalakshmi: RP- HPLC Method Development and Validation of Dapagliflozin in Bulk and Table Formulation. International journal of pharmacy and analytical research 2013; 2(4): 221-226.
Sundar SP, Vasanthi R, Raja AM, Dutt RK, Rao KNV and Ramana H: Development and Validation of RP-HPLC method for simultaneous estimation of Dapagliflozin and Metformin in bulk and in synthetic Mixture. World journal of pharmacy and pharmaceutical sciences 2017; 6(7): 2139-2150.
Jitendra D, Kumar S, Kumar SJ and Khan A: A new RP- HPLC Method Development and Validation of Dapagliflozin in bulk and tablet dosage form. International Journal of Drug development and Research 2017; 9: 48-51.
Aubry AF, Gu H. Magnier R, Morgan L, Xu X, Tirmenstein M, Wang b, Deng Y, Cai J, Couerbe P and Arnold M: Validated LCMS/MS methods for the determination of Dapagliflozin, a Sodium glucose co- transporter 2 Inhibitor in Normal and ZDF rat Plasma. Bio Analysis 2010; 2(12): 2001-2009.
Squibb BM and AstraZeneca: Chromatography and Tandem mass Spectroscopy method for the quantitative determination of Saxagliptin and its major pharmacologically active 5-Monohydroxy Metabolite in human plasma. Journal of chromatography B 2012.
Vundavilli JK: Development and Validation of tempo content in Saxagliptin by GC. International journal of advances in pharmacy, biology, and chemistry 2017; 6(1): 37-45.
ICH Harmonised Tripartite Guideline, Validation of analytical procedures: Text and methodology, Q2 (R1), International Conference on Harmonization, Geneva. 2005; 1-13.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
